Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F13%3A00058800" target="_blank" >RIV/00023001:_____/13:00058800 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/13:N0000013

Výsledek na webu

<a href="http://jama.jamanetwork.com/article.aspx?articleid=1666394" target="_blank" >http://jama.jamanetwork.com/article.aspx?articleid=1666394</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1001/jama.2013.1954" target="_blank" >10.1001/jama.2013.1954</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial

Popis výsledku v původním jazyce

IMPORTANCE:Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. OBJECTIVE: To investigate whether aliskiren, a direct renin inhibitor, when added to standard therapy, would reduce the rate of cardiovascular (CV) death or HF rehospitalization among HHF patients. INTERVENTION: All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months. MAIN OUTCOME MEASURES Cardiovascular death or HF rehospitalization at 6 months and 12 months. RESULTS: In total, 1639 patients were randomized, with 1615 patients included in the final efficacyanalysis cohort (808 aliskiren, 807 placebo). Mean age was 65 years; mean LVEF, 28%; 41% of patients had diabetes mellitus, mean estimated glomerular filtration rate, 67 mL/min/1.73 m2. At admission and randomization, median NT-proBNP lev

Název v anglickém jazyce

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial

Popis výsledku anglicky

IMPORTANCE:Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. OBJECTIVE: To investigate whether aliskiren, a direct renin inhibitor, when added to standard therapy, would reduce the rate of cardiovascular (CV) death or HF rehospitalization among HHF patients. INTERVENTION: All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months. MAIN OUTCOME MEASURES Cardiovascular death or HF rehospitalization at 6 months and 12 months. RESULTS: In total, 1639 patients were randomized, with 1615 patients included in the final efficacyanalysis cohort (808 aliskiren, 807 placebo). Mean age was 65 years; mean LVEF, 28%; 41% of patients had diabetes mellitus, mean estimated glomerular filtration rate, 67 mL/min/1.73 m2. At admission and randomization, median NT-proBNP lev

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JAMA

ISSN

0098-7484

e-ISSN

—

Svazek periodika

309

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

1125-1135

Kód UT WoS článku

000316276500026

EID výsledku v databázi Scopus

—